Citation

Davis MT, Hillmer A, Holmes SE, Pietrzak RH, DellaGioia N, Nabulsi N, Matuskey D, Angarita G, Carson RE, Krystal JH, Esterlis I. Proc. Natl. Acad. Sci. U. S. A. 2019; 116(23): 11490-11495.

Copyright

(Copyright © 2019, National Academy of Sciences)

DOI

10.1073/pnas.1818871116

PMID

31085640

PMCID

PMC6561298

Abstract

Recent evidence implicates dysregulation of metabotropic glutamatergic receptor 5 (mGluR5) in pathophysiology of PTSD and suicidality. Using positron emission tomography and [18F]FPEB, we quantified mGluR5 availability in vivo in individuals with PTSD (n = 29) and MDD (n = 29) as a function of suicidal ideation (SI) to compare with that of healthy comparison controls (HC; n = 29). Volume of distribution was computed using a venous input function in the five key frontal and limbic brain regions. We observed significantly higher mGluR5 availability in PTSD compared with HC individuals in all regions of interest (P's = 0.001-0.01) and compared with MDD individuals in three regions (P's = 0.007). mGluR5 availability was not significantly different between MDD and HC individuals (P = 0.17). Importantly, we observed an up-regulation in mGluR5 availability in the PTSD-SI group (P's = 0.001-0.007) compared with PTSD individuals without SI.

FINDINGS point to the potential role for mGluR5 as a target for intervention and, potentially, suicide risk management in PTSD.

Language: en

Keywords

Humans; Adult; Female; Male; PTSD; Suicidal Ideation; Biomarkers; suicidal ideation; Suicide Prevention; Brain; Depressive Disorder, Major; PET; Positron-Emission Tomography; Radiopharmaceuticals; mGluR5; Receptor, Metabotropic Glutamate 5